An experimental drug called, veliparib, is being studied for treatment of patients with squamous NSCLC. This drug is a "PARP" inhibitor and may be used with chemotherapy or radiation to help improve efficacy. Although it's too early to tell if this drug will be FDA-approved, the possibility of having another treatment option is exciting news. A press release can be found here: biospace.com/News/abbvie-re...
FDA grants orphan drug status to an ex... - Lung Cancer Support
FDA grants orphan drug status to an experimental drug for squamous NSCLC
Written by
MFH_Advocate
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
FDA approval for Investigational drug Small Cell Lung Cancer
Hello all,
FDA approved APG-1252 as a investigational drug for treatment for small cell on or about...
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the...
A new drug for ALK-positive lung cancer approved today
The FDA has approved a new drug for patients with ALK-positive lung cancer. The drug is called...
First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)
On December 18th, 2020, the Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for...
Opdivo and Yervoy combination approved for Non-small cell lung cancer
More exciting approval announcements for this week.
On May 15th, 2020, the Food and Drug...
FDA Approves Keytruda Combo for Lung Cancer
DCIS Breast Cancer and Small Cell Lung Cancer Patient
Pet Scan results are back
